ArticleFrontiers in genetics2026
Genomic innovation in precision oncology: integrated CRISPR-TTP bioengineering architecture for Ewing Sarcoma (version 4.0 - complete architectural specification).
Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metastatic Ewing Sarcoma remains a critical therapeutic challenge with 5-year survival below 30%. The EWSR1-FLI1 fusion oncogene is undruggable by conventional approaches, requiring integrated bioengineering solutions. Architecture: We present CRISPR-TTP, a modular architecture combining high-fidelity CRISPR-Cas9 genome engineering (>94% efficiency), FUS-programmable temporally controlled delivery via HOF-nanoparticles (1-2 mm spatial resolution), dendritic cell autovaccination, and PD-1 blockade. A multimodal AI system orchestrates real-time personalization and optimization. Projected Efficacy: In silico modeling predicts ∼96.3% tumor growth inhibition and a ∼65% improvement in median survival. CD8 Conclusion: This CC0-licensed architecture defines a new standard for integrated, spatiotemporally programmable precision oncology and is suitable for compassionate-use-ready translational deployment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.